Avid Bioservices Inc (CDMO)

[nuke661]

PGG76109,

Thanks for that link to the HIV poster info.

Anyone have an educated/knowledgeable insight regarding the possible importance of the last sentence of the conclusion section:

"Incidentally,we have developed a Master Cell Bank (MCB) of a cell line that stably expresses PGN632. mAb from this MCB was also able to neutralize HIV-1 in vitro to the same degree as reported here (data not shown)."

Is this making a statement that the mAb can now be produced much easier? Meaning cheaper and in far greater quantities per production run? Is this saying there is now a manufacturing capability that can produce a strong HIV-1 inhibitor for a "small??" fraction of what previous costs were? Or is this just a statement they have the capability to produce the mAb in quantity in manufacturing runs and implies nothing about the cost?

I would appreciate anyone who can interpret this for us to do so.

Thank you.